UK Markets closed

MEDIQON Group AG: Conclusion of an Investment Agreement

  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

DGAP-News: MEDIQON Group AG / Key word(s): Capital Increase
04.11.2021 / 18:33
The issuer is solely responsible for the content of this announcement.

MEDIQON Group AG: Conclusion of an Investment Agreement

As announced in the 04/11/2021, 18.20 ad-hoc notice, management and supervisory boards of MEDIQON Group AG have resolved on a 10% cash capital increase from authorized capital (up to 999,955 shares) today. In addition, it was decided to start preparations of an additional capital increase via rights issue for 3,999,824 shares, most likely to take place in 2022.

In the context of both capital increases, MEDIQON concluded an Investment Agreement with a group of institutional investors.

Sator Grove Holdings LLC as Lead-Investor and three other renowned institutional investors intend to invest more than EUR 40 million cumulated in both capital increases. In particular, the Investment Agreement relates to the placement of any possible share overhang in the forthcoming 2022 rights issue.

It is intended to set the subscription price of the 2022 rights issue with a similar logic as the price of today's placement, while also incorporating the operating development of MEDIQON's platform companies.

Jan-Hendrik Mohr, CEO of MEDIQON Group AG:

"We are delighted to receive such great support from institutional investors to further enhance the growth of MEDIQON. The team at Sator Grove has long experience investing in decentralized holding companies in general and vertical market software in particular. Additionally, Sator Grove brings both a permanent capital structure and strategic shareholder base that stands out across today's institutional landscape. We are now set with optimal resources to help scale the platform companies of MEDIQON for many years to come!"

Paul Buser, Co-Founder and Co-CEO, Sator Grove Holdings LLC:

"We are thrilled to be able to come alongside MEDIQON at this inflection point in the company's trajectory. Jan and his team have a proven track record and are now superbly positioned to add value to all stakeholders and to be the most desired home for high quality businesses across Germany and beyond!"

The Investment Agreement is not a formal underwriting agreement and MEDIQON is not legally bound to conduct the 2022 rights issue.

About MEDIQON Group AG:

MEDIQON is a publicly traded holding company connecting outstanding talent & investment opportunities. MEDIQON backs decentralized platform companies investing its permanent capital base to support long-term growth.

www.mediqon-group.de

About Sator Grove Holdings LLC:

Sator Grove Holdings is a permanent capital investor based in Bradenton, Florida, helping the world's top entrepreneurs, operators & investors attain the extraordinary. With a vision to create a thriving ecosystem rooted in love and centered upon company building, they do this by providing enduring capital and also by enabling their company holdings to achieve their full potential. In doing so, they seek to invert the traditional relationship between shareholders and companies. The essence of Sator Grove is first a flourishing community that seeks to do good together and second an investment company. Sator Grove's shareholders include several world-class company CEOs and investors, and together, Sator Grove's aim is to 'sow good seeds' that grow into win-win outcomes for all constituents, including society and future generations.

www.satorgrove.com


04.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

MEDIQON Group AG

Herzog-Adolph-Strasse 2

61462 Königstein im Taunus

Germany

Phone:

+49 (0) 6174-9687040

Fax:

+49 (0) 6174-9687043

E-mail:

ir@mediqon-group.de

Internet:

www.mediqon-group.de

ISIN:

DE0006618309, DE000A254TL0

WKN:

661830, A254TL

Listed:

Regulated Unofficial Market in Berlin, Frankfurt (Basic Board), Stuttgart

EQS News ID:

1246427


 

End of News

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting